Wall Street Zen Downgrades MediWound (NASDAQ:MDWD) to Strong Sell

Key Points

• Wall Street Zen downgraded MediWound to “strong sell” from “sell,” while the broader analyst consensus remains “Hold” with an average price target of $33.00.
• MediWound shares opened at $13.56, near their 12-month low of $13.40, and trade below both their 50-day and 200-day moving averages.
• The company slightly missed quarterly earnings expectations, reporting a loss of $0.77 per share versus the anticipated $0.76 loss, though revenue of $3.09 million exceeded estimates of $2.59 million.

MediWound (NASDAQ:MDWD - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "sell" rating to a "strong sell" rating in a research note issued to investors on Saturday.

MDWD has been the subject of a number of other research reports. Oppenheimer reaffirmed an "outperform" rating and set a $30.00 price target (down from $32.00) on shares of MediWound in a research report on Friday. HC Wainwright reissued a "buy" rating and issued a $36.00 price objective on shares of MediWound in a report on Thursday, May 28th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of MediWound in a research note on Friday, July 17th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $33.00.

MediWound Trading Up 0.2%

NASDAQ MDWD opened at $13.56 on Friday. The company has a fifty day simple moving average of $14.35 and a two-hundred day simple moving average of $15.97. The stock has a market cap of $174.25 million, a P/E ratio of -7.53 and a beta of 0.15. MediWound has a 12-month low of $13.40 and a 12-month high of $20.30.

MediWound (NASDAQ:MDWD - Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.01). The company had revenue of $3.09 million for the quarter, compared to analysts' expectations of $2.59 million. MediWound had a negative net margin of 170.10% and a negative return on equity of 44.77%. As a group, sell-side analysts forecast that MediWound will post -2.31 earnings per share for the current year.

Insider Activity at MediWound

In related news, Director David Morton Fox bought 3,537 shares of the stock in a transaction dated Monday, June 1st. The shares were purchased at an average price of $14.11 per share, for a total transaction of $49,907.07. Following the completion of the purchase, the director directly owned 22,283 shares of the company's stock, valued at $314,413.13. This represents a 18.87% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 9.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Kotler Kevin acquired a new stake in shares of MediWound during the 4th quarter valued at about $6,225,000. Millennium Management LLC raised its holdings in MediWound by 355.6% in the 3rd quarter. Millennium Management LLC now owns 175,383 shares of the biopharmaceutical company's stock worth $3,160,000 after purchasing an additional 136,884 shares during the period. UBS Group AG boosted its position in MediWound by 90.1% during the fourth quarter. UBS Group AG now owns 145,057 shares of the biopharmaceutical company's stock worth $2,678,000 after purchasing an additional 68,756 shares in the last quarter. Sphera Funds Management LTD. boosted its position in MediWound by 24.3% during the fourth quarter. Sphera Funds Management LTD. now owns 230,347 shares of the biopharmaceutical company's stock worth $4,252,000 after purchasing an additional 45,077 shares in the last quarter. Finally, Summit Financial LLC boosted its position in MediWound by 200.1% during the fourth quarter. Summit Financial LLC now owns 47,998 shares of the biopharmaceutical company's stock worth $886,000 after purchasing an additional 32,006 shares in the last quarter. 46.83% of the stock is owned by institutional investors and hedge funds.

MediWound Company Profile

MediWound Ltd. NASDAQ: MDWD is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company's lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source